These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28074349)

  • 1. Second-Generation Antipsychotic Utilization and Metabolic Parameter Monitoring in an Inpatient Pediatric Population: A Retrospective Analysis.
    Nolt VD; Kibler AV; Wilkening GL; Fabian TJ
    Paediatr Drugs; 2017 Apr; 19(2):139-146. PubMed ID: 28074349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study.
    Ronsley R; Nguyen D; Davidson J; Panagiotopoulos C
    Can J Psychiatry; 2015 Oct; 60(10):441-50. PubMed ID: 26720191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics.
    Krane-Gartiser K; Breum L; Glümrr C; Linneberg A; Madsen M; Køster A; Jepsen PW; Fink-Jensen A
    Nord J Psychiatry; 2011 Oct; 65(5):345-52. PubMed ID: 21428861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic Monitoring of Child and Adolescent Patients on Atypical Antipsychotics by Psychiatrists and Primary Care Providers.
    Wakefield S; Aligeti M; Rachamallu V; Baronia R; Aynampudi R; Parmar A; Peterson P; Masodkar K
    Am J Ther; 2020; 27(5):e425-e430. PubMed ID: 30762589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Metabolic Syndrome in Drug-Naive Adolescents After 12 Months of Second-Generation Antipsychotic Treatment.
    Sjo CP; Stenstrøm AD; Bojesen AB; Frølich JS; Bilenberg N
    J Child Adolesc Psychopharmacol; 2017 Dec; 27(10):884-891. PubMed ID: 28783382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a computer-based intervention to enhance metabolic monitoring in psychiatry inpatients treated with second-generation antipsychotics.
    DelMonte MT; Bostwick JR; Bess JD; Dalack GW
    J Clin Pharm Ther; 2012 Dec; 37(6):668-73. PubMed ID: 22845616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic monitoring of patients prescribed second-generation antipsychotics.
    Dhamane AD; Martin BC; Brixner DI; Hudson TJ; Said Q
    J Psychiatr Pract; 2013 Sep; 19(5):360-74. PubMed ID: 24042242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of a computerized best practice alert system in an outpatient setting on metabolic monitoring in patients on second-generation antipsychotics.
    Cohen S; Bostwick JR; Marshall VD; Kruse K; Dalack GW; Patel P
    J Clin Pharm Ther; 2020 Dec; 45(6):1398-1404. PubMed ID: 32767599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of Recommended Metabolic Laboratory Parameters Among Medicaid Recipients on Second-Generation Antipsychotics in Federally Qualified Health Centers.
    Uzal NE; Chavez B; Kosirog ER; Billups SJ; Saseen JJ
    Ann Pharmacother; 2018 Feb; 52(2):160-165. PubMed ID: 28884591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications.
    Panagiotopoulos C; Ronsley R; Davidson J
    Can J Psychiatry; 2009 Nov; 54(11):743-9. PubMed ID: 19961662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic monitoring of pediatric patients prescribed second-generation antipsychotic medication.
    Roebuck JH
    J Child Adolesc Psychiatr Nurs; 2024 Feb; 37(1):e12438. PubMed ID: 37586850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in body mass index z-scores and weight status in a Dutch pediatric psychiatric population with and without use of second-generation antipsychotics.
    de Hoogd S; Overbeek WA; Heerdink ER; Correll CU; de Graeff ER; Staal WG
    J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):166-73. PubMed ID: 22506734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-dependent metabolic effects of second-generation antipsychotics in second-generation antipsychotic-naïve French Canadian patients.
    Roy G; Bedard A; Desmarais PA; Jourdain F; Allen S; Michaud D; Ben Amor L
    J Child Adolesc Psychopharmacol; 2010 Dec; 20(6):479-87. PubMed ID: 21186966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
    Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
    Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths.
    Rubin DM; Kreider AR; Matone M; Huang YS; Feudtner C; Ross ME; Localio AR
    JAMA Pediatr; 2015 Apr; 169(4):e150285. PubMed ID: 25844991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment.
    Calarge CA; Nicol G; Schlechte JA; Burns TL
    J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):120-9. PubMed ID: 24725198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics.
    Weissman EM; Zhu CW; Schooler NR; Goetz RR; Essock SM
    J Clin Psychiatry; 2006 Sep; 67(9):1323-6. PubMed ID: 17017817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia.
    Sugai T; Suzuki Y; Fukui N; Ono S; Watanabe J; Tsuneyama N; Someya T
    J Clin Psychopharmacol; 2012 Jun; 32(3):390-3. PubMed ID: 22544005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
    Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
    Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.